GOLD 2023 KEY CHANGES SUMMARY

References, Tables & Figures

In total **387 new references** have been added to the GOLD 2023 report as listed alphabetically at the end of this document.

Tables and Figures have been redesigned and minor amendments and corrections have been made to many. In addition, the following new Tables and Figures have been added to the GOLD 2023 report:

**Table 1.1** Proposed Taxonomy (Etiotypes) for COPD

**Table 2.8** Use of CT in Stable COPD

**Figure 3.2** Overview of Current and Proposed Surgical and Bronchoscopic Interventions for People with COPD

**Table 3.6** Evidence Supporting a Reduction in Mortality with Pharmacotherapy and Non-pharmacotherapy in COPD Patients

**Table 4.5** Basic Principles for Appropriate Inhalation Device Choice

**Table 5.3** Diagnosis and Assessment

**Chapter 1**

► Chapter 1 has been rewritten to incorporate new background information on COPD and new strategies for terminology and taxonomy
► A new definition of COPD has been proposed (Page 5)
► A section on Chronic Bronchitis has been added (Page 13)
► A table has been added with Proposed Taxonomy (Etiotypes) for COPD (Table 1.1)

**Chapter 2**

► Additional information on screening for COPD and case-finding has been included (Page 36)
► Information on Imaging and Computed Tomography (CT) has been included (Page 43)
► A table with information on the Use of CT in Stable COPD has been added (Table 2.8)

**Chapter 3**

► Vaccination Recommendations for people with COPD have been updated in line with current guidance from the CDC (Page 54)
► Further information on therapeutic interventions to reduce COPD mortality has been added (Page 67)
► A table has been added with information on the Evidence Supporting a Reduction in Mortality with Pharmacotherapy and Non-pharmacotherapy in COPD Patients (Table 3.6)
► Issues Related to Inhaled Delivery have been addressed (Page 69)
► Information on the topic of Adherence to Inhaled COPD Medications has been included (Page 71)
► A section on Tele-rehabilitation has been added (Page 76)
► The section on Interventional & Surgical Therapies for COPD has been expanded (Page 82)
► A figure has been added giving an Overview of Current and Proposed Surgical and Bronchoscopic Interventions
for People with COPD (Figure 3.2)

Chapter 4

► A section on the choice of inhaler device has been added (Page 112)
► A table has been added with information on Basic Principles for Appropriate Inhalation Device Choice (Table 4.5)
► The ABCD Assessment Tool has been revised to the ABE Assessment Tool to recognize the clinical relevance of exacerbations, independent of the level of symptoms (Page 115)
► The information and figures outlining Initial Pharmacological Treatment and Follow-up Pharmacological Treatment have been updated. In particular, the positioning of LABA+LAMA and of LABA+ICS has been changed (Page 115)

Chapter 5

► The topic of management of exacerbations has been expanded to include details of possible alternative causes of symptoms
► A new definition of COPD Exacerbation and a new set of parameters to assess exacerbation severity at the point of care has been included (Page 134)
► A new table on Diagnosis and Assessment has been added (Table 5.3)

Chapter 6

► The chapter on COPD and Comorbidities has been updated with the latest evidence.

Chapter 7

► The chapter on COVID-19 and COPD has been updated with new references and the latest evidence.

NEW REFERENCES ADDED

References added to Chapters 1-7 (listed alphabetically)


Yawn BP, Han M, Make BM, et al. Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. *Chronic Obstr Pulm Dis* 2021; 8(1).


Zaigham S, Tanash H, Nilsson PM, Muhammad IF. Triglyceride-Glucose Index is a Risk Marker of Incident COPD Events in Women. *Int J Chron Obstruct Pulmon Dis* 2022; 17: 1393-401.


